The biotech company plans to move into the new development in 2028, consolidating other leased and owned spaces in the ...

As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots ...

The facility, which is set to open amid Biogen’s 50th anniversary, will integrate research and development, technical ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen. Yeah. Well, first, companies in our space are ...

In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead ...

Biogen Inc. will relocate its headquarters to MIT’s new Kendall Square development after leasing 580,000 square feet in the ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping ... That, along with a $165 million payment from Biogen (BIIB) it received this ...